Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, 98104 WA, USA.
Sepsis Center of Research Excellence - University of Washington (SCORE-UW), Seattle, 98104 WA, USA.
Biomark Med. 2023 May;17(9):459-464. doi: 10.2217/bmm-2023-0073. Epub 2023 Aug 31.
Explore whether plasma IL-6 levels are similar across biomarker platforms and association with COVID-19 clinical outcomes. Plasma IL-6 concentrations were measured on 191 COVID-19 patients using the Roche Elecsys IL-6 assay and the Meso Scale Discovery assay. Correlation of IL-6 levels between platforms was high (r = 0.87; 95% CI: 0.82-0.89); however, agreement was low (bias: 147.2 pg/ml; 95% limits of agreement: -489.5-783.9 pg/ml). The optimal IL-6 threshold to predict invasive mechanical ventilation and in-hospital mortality were 3- and 3.4-fold higher in Roche compared with Meso Scale Discovery, respectively. The absolute IL-6 threshold to predict outcomes was consistently higher using the Roche platform, and IL-6 thresholds to inform prognosis vary based on the biomarker platform.
探讨不同生物标志物平台之间的血浆 IL-6 水平是否相似，以及与 COVID-19 临床结局的关系。使用罗氏 Elecsys IL-6 测定法和 Meso Scale Discovery 测定法，对 191 例 COVID-19 患者的血浆 IL-6 浓度进行了测量。两个平台之间的 IL-6 水平相关性很高(r=0.87;95%CI：0.82-0.89)；然而，一致性较低(偏差：147.2pg/ml；95%置信区间：-489.5-783.9pg/ml)。与 Meso Scale Discovery 相比，罗氏的最佳 IL-6 预测值分别为 3 倍和 3.4 倍，用于预测有创机械通气和住院死亡率。使用罗氏平台预测结局的绝对 IL-6 阈值始终较高，且用于提示预后的 IL-6 阈值取决于生物标志物平台。
